Jaume Sastre-Garriga

List of Publications by Citations

168 papers	6,920 citations	46 h-index	78 g-index
193 ext. papers	8,622 ext. citations	6.1 avg, IF	5.58 L-index

#	Paper	IF	Citations
168	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. *Lancet Neurology, The*, **2016**, 15, 292-303	24.1	486
167	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. *Brain*, **2015**, 138, 1863-74	11.2	302
166	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. *Neurology*, **2008**, 70, 1079-83	6.5	265
165	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurology, The*, **2017**, 16, 797-812	24.1	243
164	Brain atrophy and lesion load predict long term disability in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1082-91	5.5	209
163	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. *Neurology*, **2006**, 67, 968-72	6.5	209
162	Deep gray matter volume loss drives disability worsening in multiple sclerosis. *Annals of Neurology*, **2018**, 83, 210-222	9.4	185
161	Measures in the first year of therapy predict the response to interferon beta in MS. *Multiple Sclerosis Journal*, **2009**, 15, 848-53	5	182
160	Progression of regional grey matter atrophy in multiple sclerosis. *Brain*, **2018**, 141, 1665-1677	11.2	146
159	Brainstem lesions in clinically isolated syndromes. *Neurology*, **2010**, 75, 1933-8	6.5	136
158	Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. *Archives of Neurology*, **2006**, 63, 1175-80		135
157	Treatment of multiple sclerosis - success from bench to bedside. *Nature Reviews Neurology*, **2019**, 15, 53-58	15	129
156	Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. *Brain*, **2005**, 128, 1454-60	11.2	123
155	A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. *Archives of Neurology*, **2009**, 66, 587-92		96
154	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Nature Reviews Neurology*, **2018**, 14, 199-213	15	95
153	Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. *Archives of Neurology*, **2005**, 62, 569-73		94
152	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. *Nature Reviews Neurology*, **2018**, 14, 75-93	15	84

151	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology*, **2008**, 63, 790-3	9.4	83
150	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. *Multiple Sclerosis Journal*, **2016**, 22, 1386-1396	5	83
149	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Multiple Sclerosis Journal*, **2014**, 20, 72-80	5	81
148	Mapping the brain pathways of declarative verbal memory: Evidence from white matter lesions in the living human brain. *NeuroImage*, **2008**, 42, 1237-43	7.9	79
147	Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. *Neuroscience and Biobehavioral Reviews*, **2013**, 37, 819-30	9	78
146	A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. *Multiple Sclerosis Journal*, **2011**, 17, 457-67	5	76
145	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. *Multiple Sclerosis Journal*, **2013**, 19, 1175-81	5	75
144	A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. *Multiple Sclerosis Journal*, **2009**, 15, 1195-205	5	74
143	Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. *NeuroImage*, **2004**, 22, 353-9	7.9	74
142	Clinical impact of early brain atrophy in clinically isolated syndromes. *Multiple Sclerosis Journal*, **2013**, 19, 1878-86	5	71
141	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. *Nature Reviews Neurology*, **2020**, 16, 171-182	15	68
140	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. *Journal of Neuroimmunology*, **2002**, 130, 194-201	3.5	68
139	THC and CBD oromucosal spray (Sativex) in the management of spasticity associated with multiple sclerosis. *Expert Review of Neurotherapeutics*, **2011**, 11, 627-37	4.3	67
138	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. *Brain*, **2018**, 141, 1075-1084	11.2	64
137	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. *Journal of Neuroinflammation*, **2014**, 11, 46	10.1	63
136	Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. *Archives of Neurology*, **2007**, 64, 411-5		63
135	Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. *Journal of Neurology*, **2006**, 253, 224-30	5.5	63
134	Neurofilament light chain level is a weak risk factor for the development of MS. *Neurology*, **2016**, 87, 1076-84	6.5	61

133	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. *Multiple Sclerosis Journal*, **2018**, 24, 1843-1851	5	60
132	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. *European Journal of Neurology*, **2021**, 28, 3384-3395	6	60
131	A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population. *Neurology*, **2010**, 75, 2033-5	6.5	57
130	The hippocampus in multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 918-926	24.1	57
129	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. *Multiple Sclerosis Journal*, **2018**, 24, 301-312	5	55
128	Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 40-5	5.5	55
127	Is inflammation important in early PPMS? a longitudinal MRI study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1255-8	5.5	55
126	Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 1036-9	5.5	54
125	Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 1076-82	5.5	52
124	Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. *Neurology*, **2005**, 65, 633-5	6.5	52
123	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. *Neurology*, **2019**, 92, 180-192	6.5	50
122	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 455-64	5	46
121	Disability progression markers over 6-12 years in interferon-Ŧtreated multiple sclerosis patients. *Multiple Sclerosis Journal*, **2018**, 24, 322-330	5	45
120	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *Lancet Neurology, The*, **2021**, 20, 653-670	24.1	44
119	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. *Multiple Sclerosis Journal*, **2015**, 21, 749-56	5	43
118	Multiple sclerosis registries in Europe - results of a systematic survey. *Multiple Sclerosis Journal*, **2014**, 20, 1523-32	5	43
117	Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. *Neuroimaging Clinics of North America*, **2017**, 27, 289-300	3	42
116	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. *European Journal of Neurology*, **2012**, 19, 899-904	6	42

115	Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. *Multiple Sclerosis Journal*, **2003**, 9, 39-43	5	42
114	APS and the brain. *Lupus*, **2003**, 12, 877-82	2.6	41
113	Significant clinical worsening after natalizumab withdrawal: Predictive factors. *Multiple Sclerosis Journal*, **2015**, 21, 780-5	5	37
112	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. *Neurology*, **2016**, 87, 1368-74	6.5	37
111	Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. *Current Opinion in Neurology*, **2016**, 29, 254-62	7.1	37
110	Interferon β1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. *Archives of Neurology*, **2011**, 68, 1421-7		34
109	Multiple sclerosis management during the COVID-19 pandemic. *Multiple Sclerosis Journal*, **2020**, 26, 1163-1171	5	34
108	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. *NeuroImage: Clinical*, **2018**, 19, 466-475	5.3	33
107	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. *Multiple Sclerosis Journal*, **2014**, 20, 1602-8	5	33
106	Multiple sclerosis registries in Europe - An updated mapping survey. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 171-178	4	33
105	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. *Radiology*, **2018**, 288, 554-564	20.5	32
104	Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. *Multiple Sclerosis Journal*, **2016**, 22, 269-78	5	32
103	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. *Neurology*, **2019**, 92, e1507-e1516	6.5	31
102	The role of the cerebellum in multiple sclerosis-150 years after Charcot. *Neuroscience and Biobehavioral Reviews*, **2018**, 89, 85-98	9	31
101	Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature. *European Journal of Neurology*, **2000**, 7, 449-53	6	31
100	Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. *Clinical Neurology and Neurosurgery*, **2006**, 108, 456-60	2	30
99	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. *Annals of Neurology*, **2001**, 49, 408-411	9.4	30
98	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. *American Journal of Neuroradiology*, **2020**, 41, 1001-1008	4.4	30

97	Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. *Multiple Sclerosis Journal*, **2006**, 12, 421-7	5	29
96	Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. *Journal of Neurology*, **2015**, 262, 2617-26	5.5	28
95	Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. *Archives of Neurology*, **2004**, 61, 222-4		27
94	Transient ischaemic attack: a common initial manifestation of cardiac myxomas. *European Neurology*, **2001**, 45, 165-70	2.1	27
93	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. *Multiple Sclerosis Journal*, **2009**, 15, 1459-65	5	26
92	Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. *Annals of Neurology*, **2020**, 88, 93-105	9.4	26
91	Predictive value of early brain atrophy on response in patients treated with interferon □*Neurology: Neuroimmunology and NeuroInflammation*, **2015**, 2, e132	9.1	25
90	Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. *Multiple Sclerosis Journal*, **2013**, 19, 245-8	5	24
89	Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. *Journal of the Neurological Sciences*, **2009**, 282, 120-4	3.2	22
88	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. *Multiple Sclerosis Journal*, **2004**, 10, 413-6	5	22
87	Risk acceptance in multiple sclerosis patients on natalizumab treatment. *PLoS ONE*, **2013**, 8, e82796	3.7	21
86	Myelopathy in seronegative Sj□gren syndrome and/or primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2003**, 9, 256-9	5	20
85	Lesion topographies in multiple sclerosis diagnosis: A reappraisal. *Neurology*, **2017**, 89, 2351-2356	6.5	19
84	Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. *NeuroImage: Clinical*, **2015**, 9, 640-7	5.3	19
83	Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis. *Disability and Rehabilitation*, **2014**, 36, 1001-5	2.4	19
82	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. *Multiple Sclerosis Journal*, **2012**, 18, 1193-6	5	19
81	Decreased MMP-9 production in primary progressive multiple sclerosis patients. *Multiple Sclerosis Journal*, **2004**, 10, 376-80	5	19
80	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. *NeuroImage*, **2017**, 163, 106-114	7.9	18

79	Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. *Acta Neurologica Scandinavica*, **2012**, 126, 24-30	3.8	18
78	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. *Journal of Neurology*, **2010**, 257, 742-6	5.5	18
77	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. *Multiple Sclerosis Journal*, **2020**, 26, 1658-1669	5	18
76	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. *Nature Reviews Neurology*, **2021**, 17, 173-184	15	18
75	Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. *Journal of Neuroimaging*, **2016**, 26, 532-8	2.8	17
74	Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load. *Neuroradiology*, **2016**, 58, 467-74	3.2	17
73	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. *Multiple Sclerosis Journal*, **2017**, 23, 556-566	5	17
72	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. *American Journal of Neuroradiology*, **2018**, 39, 399-404	4.4	16
71	Using the WHOQOL-DIS to measure quality of life in persons with physical disabilities caused by neurodegenerative disorders. *Neurodegenerative Diseases*, **2011**, 8, 178-86	2.3	15
70	Value of NMO-IgG determination at the time of presentation as CIS. *Neurology*, **2012**, 78, 1608-11	6.5	15
69	Very early scans for demonstrating dissemination in time in multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 631-5	5	15
68	Unconventional therapy in multiple sclerosis. *Multiple Sclerosis Journal*, **2003**, 9, 320-2	5	15
67	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 316-318	5.5	14
66	An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. *Multiple Sclerosis Journal*, **2016**, 22, 842-6	5	14
65	Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. *European Journal of Neurology*, **2019**, 26, 41-50	6	14
64	Keeping standards of multiple sclerosis care through the COVID-19 pandemic. *Multiple Sclerosis Journal*, **2020**, 26, 1153-1156	5	13
63	Lower motor neuron disease in a HIV-2 infected woman. *Journal of Neurology*, **2000**, 247, 718-9	5.5	13
62	Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis. *Neurology*, **2019**, 92, 296-298	6.5	13

61	Highlights from the 31st ECTRIMS congress - Barcelona 2015. *Multiple Sclerosis Journal*, **2016**, 22, 7-10	5	11
60	Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey. *PLoS ONE*, **2018**, 13, e0208004	3.7	11
59	Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis. *American Journal of Neuroradiology* , **2015**, 36, 2270-6	4.4	10
58	Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. *Journal of Neuroimaging*, **2018**, 28, 313-319	2.8	9
57	Development and pilot phase of a European MS register. *Journal of Neurology*, **2010**, 257, 1620-7	5.5	9
56	Polyglandular autoimmune syndrome type II and multiple sclerosis. *Journal of Neurology*, **2001**, 248, 330-5	5.5	9
55	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 388-391	5.5	8
54	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. *American Journal of Neuroradiology*, **2017**, 38, 1486-1493	4.4	7
53	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. *Multiple Sclerosis Journal*, **2021**, 27, 913-921	5	7
52	Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance. *Multiple Sclerosis Journal*, **2021**, 27, 989-1001	5	7
51	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. *Neuroradiology*, **2019**, 61, 667-674	3.2	6
50	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. *Journal of the Neurological Sciences*, **2015**, 359, 146-50	3.2	6
49	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. *American Journal of Neuroradiology*, **2020**, 41, 461-463	4.4	6
48	Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. *Neurology*, **2018**, 91, 622-624	6.5	6
47	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. *American Journal of Neuroradiology*, **2017**, 38, 250-256	4.4	6
46	Idiopathic inflammatory demyelinating diseases of the brainstem. *Seminars in Ultrasound, CT and MRI*, **2013**, 34, 123-30	1.7	6
45	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. *Neurology*, **2021**, 96, e482-e490	6.5	6
44	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. *NeuroImage: Clinical*, **2021**, 29, 102549	5.3	6

43	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. *Neurology*, **2021**, 97, e1641-e1652	6.5	6
42	Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. *Multiple Sclerosis Journal*, **2018**, 24, 1383-1385	5	5
41	Plasma levels of 15d-PGJ are not altered in multiple sclerosis. *European Journal of Neurology*, **2009**, 16, 1197-201	6	5
40	New treatment measurements for treatment effects on relapses and progression. *Journal of the Neurological Sciences*, **2008**, 274, 80-3	3.2	5
39	Clinically definite multiple sclerosis after radiological Schilder-like onset. *Journal of Neurology*, **2003** , 250, 871-3	5.5	5
38	Response to botulinum toxin in a case of rigid spine syndrome. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 71, 564-5	5.5	5
37	Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. *European Journal of Neurology*, **2021**, 28, 2280-2293	6	5
36	Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected?. *Multiple Sclerosis Journal*, **2016**, 22, 975-6	5	5
35	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. *Neurology*, **2021**, 96, e1561-e1573	6.5	5
34	EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. *Journal of Palliative Medicine*, **2020**, 23, 1426-1443	2.2	4
33	A validation study of manual atrophy measures in patients with Multiple Sclerosis. *Neuroradiology*, **2020**, 62, 955-964	3.2	4
32	Multiple sclerosis: Dimethyl fumarate is coming of age. *Nature Reviews Neurology*, **2016**, 12, 436-7	15	4
31	Predictive markers of disease evolution after a CIS in everyday practice. *Journal of the Neurological Sciences*, **2014**, 343, 8-14	3.2	4
30	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. *Multiple Sclerosis Journal*, **2018**, 24, 721-727	5	3
29	Diagnosis and trials of clinically isolated syndrome. *Lancet Neurology, The*, **2014**, 13, 962-3	24.1	3
28	Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. *European Radiology*, **2017**, 27, 1361-1368	8	3
27	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	3
26	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. *Annals of Clinical and Translational Neurology*, **2021**, 8, 2235	5.3	3

25	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. *European Journal of Neurology*, **2021**,	6	3
24	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. *European Journal of Neurology*, **2021**, 28, 2533-2542	6	3
23	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. *Journal of Neurology*, **2021**, 1	5.5	3
22	Editorial. *Multiple Sclerosis Journal*, **2019**, 25, 1335-1336	5	2
21	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. *Multiple Sclerosis Journal*, **2015**, 21, 1802-10	5	2
20	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. *Multiple Sclerosis Journal*, **2021**, 13524585211010082	5	2
19	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. *Multiple Sclerosis Journal*, **2021**, 27, 968-972	5	2
18	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	2
17	Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary. *Multiple Sclerosis Journal*, **2018**, 24, 1539-1540	5	1
16	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. *Multiple Sclerosis Journal*, **2021**, 13524585211045545	5	1
15	An Expert Patient Program as a Tool to Empower People With Multiple Sclerosis. *Journal of Neuroscience Nursing*, **2020**, 52, 166-171	1.5	1
14	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2020**, 6, 2055217320907951	2	1
13	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. *Frontiers in Neurology*, **2021**, 12, 693333	4.1	1
12	Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region. *European Journal of Neurology*, **2021**, 28, 4124-4134	6	1
11	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. *Multiple Sclerosis Journal*, **2022**, 13524585221089540	5	1
10	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. *Journal of Neurology*, **2022**, 269, 1764	5.5	0
9	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211053001	5	0
8	Adding brain volume measures into response criteria in multiple sclerosis: the RB-4 score. *Neuroradiology*, **2021**, 63, 1031-1041	3.2	0

7	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. *NeuroImage: Clinical*, **2021**, 30, 102659	5.3	0
6	Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. *Multiple Sclerosis and Related Disorders*, **2021**, 55, 103146	4	0
5	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations.. *NeuroImage: Clinical*, **2022**, 34, 102967	5.3	0
4	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. *Neuroscience Informatics*, **2022**, 100071		0
3	"Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - NO. *Multiple Sclerosis Journal*, **2018**, 24, 576-577	5	
2	Daclizumab to treat multiple sclerosis399-404		
1	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach.. *Neuroradiology*, **2022**, 1	3.2	